Evofem Biosciences, Inc.
EVFMOTCHealthcare● Active
$0.01
$-0.00(-8.54%)
Market Cap$993975
P/E Ratio—
52W High$0.02
52W Low$0.001
Evofem Biosciences, Inc. (EVFM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EVFM · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $20.18M | $19.36M | $18.22M | $16.84M | $8.24M |
| Cost of Revenue | $5.12M | $3.83M | $6.51M | $4.42M | $4.05M |
| Gross Profit | $15.07M | $15.53M | $11.71M | $12.42M | $4.19M |
| Gross Margin %(computed) | 74.65% | 80.20% | 64.26% | 73.78% | 50.81% |
| Operating Expenses | |||||
| R&D Expenses | $3.45M | $1.84M | $2.94M | $25.03M | $33.13M |
| G&A Expenses | $7.39M | $11.56M | $14.95M | $27.56M | $24.71M |
| Total Operating Expenses | $13.63M | $23.20M | $29.55M | $96.55M | $170.99M |
| Operating Income | $1.44M | ($7.68M) | ($17.85M) | ($84.12M) | ($166.80M) |
| Operating Margin %(computed) | 7.13% | -39.64% | -97.96% | -499.64% | — |
| Interest Income | $0.01M | $0.02M | $0.03M | $0.09M | $0.01M |
| Interest Expense | $2.63M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | $0.39M | ($8.86M) | $53.00M | ($76.65M) | ($205.18M) |
| Income Tax Expense | $0.00M | $0.00M | $0.02M | $0.04M | $0.02M |
| Net Income | $0.39M | ($8.86M) | $52.98M | ($76.70M) | ($205.19M) |
| Net Margin %(computed) | 1.94% | -45.76% | 290.81% | -455.53% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.00 | $-0.09 | $10.36 | $-164.59 | $-2962.49 |
| Wtd Avg Shares | 123.66M | 96.46M | 4.83M | 0.47M | 0.07M |
| EBITDA | $2.06M | ($6.92M) | ($16.07M) | ($82.08M) | ($165.78M) |
| EBITDA Margin %(computed) | 10.23% | -35.74% | -88.19% | -487.49% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Evofem Biosciences, Inc. data
About Evofem Biosciences, Inc. (EVFM) Income Statement
Evofem Biosciences, Inc. (EVFM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EVFM reported revenue of $0.02B, gross profit of $0.02B (gross margin 74.65%), and net income of $0.00B — a net profit margin of 1.94%.
Frequently asked questions
EVFM · 4 questionsEvofem Biosciences, Inc. (EVFM) reported revenue of $0.02B for 2025, up 4.2% year-over-year.
EVFM revenueEVFM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09